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INTRODUCTION
Radioiodine (RI) ablation is commonly performed to remove re-
maining thyroid tissue in patients that have undergone total thy-
roidectomy for differentiated thyroid cancer. However, after RI 
therapy, patients often complain of painful salivary gland (SG) 
swelling, xerostomia, taste alterations, and oral infections. RI-in-
duced sialadenitis has been reported to occur in 2% to 67% of 
patients that undergo RI therapy, and thus, this condition subse-
quently diminishes quality of life for many thyroid cancer pa-
tients [1].
It is known that radiation damages DNA by producing free 
radicals, and thus, free radical scavengers can be used to protect 
tissues [2]. Amifostine is the only radioprotective drug that acts 
by scavenging free radicals and accumulates in SGs, but it does 
not protect tumor cells [3,4]. Amifostine can be used in patients 
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Objectives. Radioiodine (RI) therapy is known to subject cellular components of salivary glands (SG) to oxidative stress 
leading to SG dysfunction. However, the protective effects of antioxidants on RI-induced SG damage have not been 
well investigated. The authors investigated the morphometric and functional effects of epigallocatechin-3-gallate 
(EGCG) administered prior to RI therapy and compared this with the effects of amifostine (a well-known antioxidant) 
 in a murine model of RI sialadenitis.
Methods. Four-week-old female C57BL/6 mice (n=48) were divided into four groups; a normal control group, a RI-treated 
group (0.01 mCi/g mouse, orally), an EGCG and RI-treated group, and an amifostine and RI-treated group. Animals 
in these groups were divided into 3 subgroups and euthanized at 15, 30, and 90 days post-RI treatment. Salivary flow 
rates and lag times were measured, and morphologic and histologic examinations and TUNEL (terminal deoxynucle-
otidyl transferase biotin-dUDP nick end labeling) assays were performed. Changes in salivary 99mTc pertechnetate 
uptake and excretion were followed by single-photon emission computed tomography.
Results. Salivary flow rates and lag times to salivation in the EGCG or amifostine groups were better than in the RI-treated 
group. Histologic examinations of SGs in the EGCG or amifostine group showed more mucin-rich parenchyma and 
less periductal fibrosis than in the RI-treated group. Fewer apoptotic cells were observed in acini, ducts, and among 
endothelial cells in the EGCG or amifostine group than in the RI group. In addition, patterns of 99mTc pertechnetate 
excretion were quite different in the EGCG or amifostine group than in the RI group.
Conclusion. EGCG supplementation before RI therapy could protect from RI-induced SG damage in a manner comparable 
to amifostine, and thus, offers a possible means of preventing SG damage by RI.
Keywords. Radiation; Salivary Glands; Thyroid Neoplasms; Tomography, Emission-Computed, Single-Photon; Models, Animal
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with head and neck cancer undergoing external radiation thera-
py, but has severe adverse effects that sometimes result in dis-
continuation. Limited studies have reported on the use of ami-
fostine to protect against internal RI exposure in differentiated 
thyroid carcinoma, but results vary [5,6].
The efficacies of many natural antioxidants are being investi-
gated in terms of protection against radiation-induced tissue 
damage, and one of these, epigallocatechin-3-gallate (EGCG) is 
known to have various beneficial effects, such as, radioprotec-
tive [7-9], chemo preventive, antiapoptotic, and anti-inflamma-
tory effects [10-12]. Although RI therapy is known to induce ox-
idative stress affecting the cellular components of SGs, its pro-
tective effects on RI-induced SG damage have not been well in-
vestigated. In this study, we investigated the morphometric and 
functional effects of EGCG administered prior to RI therapy 
and compared this with the effects of amifostine (a well-known 
antioxidant) in a murine model of RI sialadenitis.
MATERIALS AND METHODS
Animal studies
Sixty-four female, 4-week-old, C57BL/6 mice weighing 18–22 g 
obtained from the Animal House Facility, International Cancer 
Research Centre (Korea), were maintained under controlled 
temperature/light conditions in an animal house with free access 
to water and a standard mouse diet. Animal studies were per-
formed in compliance with guidelines issued by the Internation-
al Cancer Research Centre Institutional Animal Ethics Commit-
tee. Animals were divided into the following 4 groups (12 ani-
mals per group): group I, the normal control; group II, RI ex-
posed group (0.01 mCi/g body weight, 131I; New Korea Industri-
al, Seoul, Korea, orally); group III, EGCG (40 mg/kg; Santa 
Cruz, CA, USA, intraperitoneally [i.p.]) 6 hours and 30 minutes 
before RI exposure; and group IV, administration of amifostine 
(200 mg/kg; TCI, Tokyo, Japan, i.p.) 30 minutes before RI expo-
sure. Groups were divided into 3 subgroups based on time of 
sacrifice (15, 30, or 90 days post-RI). Experimental animals 
were administered 1.5 µg/100 g of thyroxine and 1% calcium 
lactate in drinking water to maintain an euthyroid state.
Measurements of body weights, salivary gland weights,  
salivary lag times, and salivary flow rates
Mice were weighed and administered ketamine (100 mg/kg) 
and xylazine (5 mg/kg) in sterile water by intraperitoneal injec-
tion. A fresh solution of pilocarpine (0.5 mg/mL) was prepared 
in phosphate buffered saline, and 0.01-mL/g body weight i.p. 
was administered to each mouse. Saliva was collected for 10 
minutes after pilocarpine administration with mice positioned 
vertically (head-down). Salivary lag times were measured and 
saliva was collected for 10 minutes in preweighed 0.75-mL Ep-
pendorf tubes. Immediately after saliva collection, mice were 
euthanized by cervical dislocation. Submaxillary glands and 
tongues were excised.
Morphological analysis of tissues and TUNEL assay
SGs and tongues were immediately placed in 4% paraformalde-
hyde at room temperature, embedded in paraffin, and sectioned 
at 4 μm. SGs were stained with alcian blue (AB) and Masson’s 
trichrome (MT), and tongues were stained with hematoxylin 
and eosin (H&E).
Apoptosis in submaxillary gland tissues was determined using 
a terminal deoxynucleotidyl transferase biotin-dUDP nick end 
labeling (TUNEL) assay using an ApopTag Plus in situ Apoptosis 
Kit (Chemicon Int., Temecula, CA, USA). TUNEL-positive cells 
were detected at a magnification of ×400, and numbers of TU-
NEL-positive cells were counted in 10 random high power 
fields. TUNEL assays were performed at 15, 30, and 90 days 
post-RI exposure.
SPECT protocol of animals study
At 90 days post-RI, technetium pertechnetate (55.5 MBq, [99mTc]
TcO4–; New Korea Industrial) was administered i.p. to anesthe-
tized mice, which were maintained in an unconscious state dur-
ing the entire imaging protocol using isoflurane (2 volume % in 
air). Whole-body single photon emission computed tomography 
(SPECT) imaging was started immediately after the [99mTc]
TcO4– injection and repeated every 5 minutes for 100 minutes 
(NanoSPECT; Bioscan Inc., Washington, DC, USA). Overall, 21 
images were obtained per mouse. A fresh solution of pilocarpine 
(0.5 mg/mL) was then prepared in phosphate buffered saline, 
and administered at 0.01 mL/g body weight (i.p.), 60 minutes 
after SPECT.
Whole body SPECT protocol
Whole body SPECT images were obtained using a large field-of-
view rotating gamma camera equipped with four multi-pinhole 
collimators. The acquisition parameters used were; 24 projec-
tions over 360°, circular orbit, and a total acquisition time of 6 
minutes (4 seconds per projection). Tomographic images were 
reconstructed using an iterative reconstruction algorithm 
[13,14].
   Salivary functions in the epigallocatechin-3-gallate (EGCG) 
groups were better than in the radioiodine group.
   EGCG group showed more mucin-rich parenchyma and less 
periductal fibrosis.
   Fewer apoptotic cells were observed in EGCG group than in 
radioiodine group. 
   EGCG supplementation could protect from radioiodine-in-
duced salivary gland damage. 
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SPECT image analysis
SPECT images were reviewed and processed using InVivoScope 
(Bioscan Inc.) and Osirix imaging software (The Osirix Founda-
tion, Geneva, Switzerland). Regions of interest (ROIs) were first 
drawn manually around thyroid and SGs on images obtained 60 
minutes posttreatment that best showed contours of the thyroid 
and SGs. ROIs of each lesion were combined into a volume of 
interest (VOI) and VOIs were copied and pasted onto SPECT 
images, except for images obtained at 60 minutes posttreatment. 
All VOIs were corrected to ensure they did not contain noise 
counts from neighboring tissues, such as, bone. The radioactivi-
ties of all voxels in VOIs were measured and corrected for activi-
ty decay posttreatment. Maximal normalized radioactivity in 
VOIs were used as representative values to minimize partial-
volume effects.
Statistical analysis
Data analysis was performed using Graph Pad Prism 5 package 
(GraphPad Software Inc., La Jolla, CA, USA). The significances 
of differences between groups were evaluated using the Kruskal-
Wallis test followed by post hoc testing with Dunn’s test. P-val-
ues of <0.05 were considered statistically significant. All results 
are expressed as means±SDs.
RESULTS
Changes in body and salivary gland weights
Before the experiment, no significant weight difference was ob-
served between the all groups (P>0.05). However, at 15, 30, 
and 90 days posttreatment, mice in the RI group weighed signif-
icantly less than mice in the normal control group, and mice in 
the EGCG group weighed significantly more than mice in the RI 
group (all P<0.05, respectively) (Fig. 1A). Animals in the ami-
fostine group weighed significantly more than animals in the RI-
exposed group at 90 days post-RI (P<0.05) (Fig. 1A). At 15 and 
30 days posttreatment, mice in the EGCG group weighed signif-
icantly more than mice in the amifostine group (both P<0.05, 
respectively) (Fig. 1A). SG weights were no different in the 4 
groups at 15 and 90 days post-RI (all P>0.05, respectively) (Fig. 
1B). However, SGs in the normal control weighed significantly 
more than those in the other 3 groups at 30 days post-RI 
(P<0.05) (Fig. 1B).
Salivary lag times and salivary flow rates
No significant intergroup difference was observed for lag times 
at 15 days post-RI in the RI, EGCG or amifostine group 
(P>0.05) (Fig. 1C). However, at 30 and 90 days post-RI, lag 
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Fig. 1.  Comparisons of mouse weights (A), salivary gland weights (B), salivary lag times (C), and flow rates (D). (A) Mice weight in the EGCG 
or amifostine treated groups was heavier. (B) SG weight in the normal control group was heavier. (C) Lag times and salivary flow rates in the 
EGCG or amifostine group were shorter and greater respectively. Kruskal-Wallis test and Dunn post hoc multiple comparison test (all P<0.05, 
respectively). Group I, the normal control; group II, RI exposed group; group III, administration of EGCG before RI exposure; group IV, admin-
istration of amifostine before RI exposure. EGCG, epigallocatechin-3-gallate; RI, radioiodine. a)Compared to group I. b)Compared to group II. 
c)Compared to group III.
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Fig. 2. Histological analysis of salivary glands. Mucin-containing acini stained with Alcian blue appeared to be more numerous in the EGCG or 
amifostine group than in the RI group. MT staining showed the EGCG or amifostine group exhibited less periductal and perivascular fibrosis 
than the RI group. Group I, the normal control; group II, RI exposed group; group III, administration of EGCG before RI exposure; group IV, ad-
ministration of amifostine before RI exposure. EGCG, epigallocatechin-3-gallate; RI, radioiodine; MT, Masson’s trichrome (scale bar, 20 μm).
Group Ι Group ΙΙ Group ΙΙΙ Group ΙV
MT
Fig. 3. Histological analysis of tongues. Tongue staining showed irregular epithelium, a cornified layer of filiform papillae, and debris on tongue 
surfaces in the RI group (arrowhead). However, animals in the EGCG or amifostine group showed uniform, smooth epithelium, and clean 
tongue surfaces as compared with the RI group (arrow). (A) Group I, the normal control; (B) group II, RI exposed group; (C) group III, adminis-
tration of EGCG before RI exposure; and (D) group IV, administration of amifostine before RI exposure. EGCG, epigallocatechin-3-gallate; RI, 
radioiodine (scale bar, 100 μm).
times in the EGCG or amifostine treated group were significant-
ly shorter than in the RI group (all P<0.05, respectively) (Fig. 
1C). At 90 days, lag times in the amifostine group were signifi-
cantly shorter than in the EGCG group (P<0.05) (Fig. 1C). In 
addition, no significant difference between salivary flow rates in 
the RI, EGCG, and amifostine groups at 15 and 30 days post-RI 
(all P>0.05, respectively) (Fig. 1D). At 90 days post-RI, salivary 
flow rates in the EGCG or amifostine treated group were greater 
than in the RI group (P<0.05) (Fig. 1D). There were no signifi-
cant differences between EGCG and amifostine group at 15, 30, 
and 90 days post-RI (all P>0.05, respectively) (Fig. 1D).
Histological changes and apoptosis
Microscopic histological changes in SGs were visualized by AB 
and MT staining at 90 days post-RI. Mucin-containing acini 
stained with Alcian blue appeared to be more numerous in the 
EGCG or amifostine group than in the RI group. EGCG or ami-
fostine group also exhibited less periductal and perivascular fi-
brosis than the RI group (Fig. 2). Filiform papillae of tongues 
were evaluated by H&E staining at 90 days post-RI. H&E stain-
ing revealed the RI group showed irregular epithelium on corni-
fied filiform papillae and debris on the tongue surface. However, 
the EGCG or amifostine group showed uniform, smooth epithe-
Alcian blue
A B
C D
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lium and no surface debris (Fig. 3).
TUNEL assays showed that numbers of TUNEL-positive cells 
were significantly higher in the RI group at 15, 30, and 90 days 
post-RI, and that numbers were significantly lower in the EGCG 
or amifostine group (all P<0.05, respectively) (Fig. 4A). Similar-
ly, numbers of TUNEL-positive acinar, ductal, and endothelial 
cells were significantly elevated in the RI group but not in the 
EGCG or amifostine group at 15, 30, and 90 days post-RI (all 
P<0.05, respectively) (Fig. 4B–D).
Dynamics of 99mTc pertechnetate uptake and excretion
A 90 days post-RI levels of 99mTc pertechnetate excretion were 
markedly lower in the RI group, but levels of excretion in the 
EGCG or amifostine group were similar to that in the normal 
control group (Fig. 5).
DISCUSSION
The incidence of thyroid cancer is increasing over the last few 
decades, and surgery and/or RI ablation therapy was usually 
performed to treat well differentiated thyroid cancers [15]. RI 
therapy is an excellent treatment modality for the ablation of re-
sidual tumor cells. However, RI affects many nonthyroidal tis-
sues, such as, SGs, lacrimal glands, gastric mucosa, mammary 
glands, and bone marrow. These tissues all express sodium io-
dide symporter, which mediates the active transport of iodide 
ions into cells and thyroid follicular cells in particular [16].
RI-induced sialadenitis occurs in 2% to 67% of thyroid can-
cer patients that have undergone RI therapy [17], and thus, the 
topic of sialadenitis after RI exposure has received considerable 
attention. RI has been shown to accumulate 30–40 times more 
Fig. 4. Quantitative analysis by terminal deoxynucleotidyl transferase biotin-dUDP nick end labeling (TUNEL) assay. (A) Total numbers of TU-
NEL-positive cells, (B) TUNEL-positive acinar, (C) ductal cells, and (D) endothelial cells. (A) Analysis showed that total numbers of TUNEL-
positive cells were significantly reduced in the EGCG or amifostine group as compared with RI group. (B–D) Numbers of TUNEL-positive aci-
nar, ductal, and endothelial cells were significantly higher in the RI group and decreased in EGCG or amifostine treated group. Kruskal-Wallis 
test and Dunn’s post hoc multiple comparison test (all P<0.05, respectively). Group I, the normal control; group II, RI exposed group; group III, 
administration of EGCG before RI exposure; group IV, administration of amifostine before RI exposure. EGCG, epigallocatechin-3-gallate; RI, 
radioiodine. a)Compared to group I. b)Compared to group II. c)Compared to group III.
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in SGs than in plasma, and SG dysfunction is one of the impor-
tant complications of RI therapy and one with serious impacts 
on patients. RI-induced sialadenitis, which may be transient or 
permanent, impairs quality of life [18], not only does it cause 
obstructive sialadenitis and its associated symptoms of swelling 
and pain, but in the chronic state can also cause hyposalivation. 
Because patients with differentiated thyroid cancer have a good 
prognosis, it is critical that the side effects of RI therapy be mini-
mized, and thus, the protection of SGs from RI therapy is an im-
portant issue.
In an attempt to prevent the above-mentioned complications, 
healthy SGs must be protected. The administration of a radio-
protective agent prior to radiation to prevent side effects is one 
such potential preventive measure. In vivo studies on cell pro-
tection from radical oxygen species generated by ionizing radia-
tion have been conducted over the years, and amifostine has 
been shown to have low toxicity and to protective SGs well 
from RI [19]. Amifostine has also been reported to be organ 
specific, and is considered to protect normal tissues from the 
acute and late effects of radiation in head and neck cancer. Fur-
thermore, the U.S. Food and Drug Administration (FDA) autho-
rized its use as a radioprotective agent in 1999 [20]. In fact, ami-
fostine is the only drug approved by the FDA for radioprotec-
tion in cancer patients. However, it has some adverse effects that 
can lead to its discontinuation in some patients [21]. In addition, 
its limited administration route, cost, and the need for medical 
supervision have limited its clinical use [2,22], and its beneficial 
effects in patients with thyroid cancer undergoing RI therapy 
have yet to be established [23]. Hence, the major focus of the 
present study was to develop a highly effective and nontoxic SG 
radioprotectant for therapeutic RI exposure.
Many phytochemicals have been shown to have unique abili-
ties to prevent radiation damage [24]. Recent research attention 
has focused on the protective role of EGCG in epidermal epi-
thelial cells subjected to ultraviolet exposure [7,8], and in these 
studies, EGCG was found to protect epidermal keratinocytes 
from ultraviolet induced hydrogen peroxide formation [9]. Dick-
inson et al. [25] showed that EGCG is able to restore the levels 
of antioxidant defense enzymes providing protection to the sali-
vary glands from oxidative damage in nonobese diabetic mice 
Fig. 5. Dynamics of 99mTc pertechnetate at 90 days post-RI. At 90 days posttreatment, 99mTc pertechnetate excretion was markedly lower in the 
RI-exposed group than other groups, but 99mexcretions in the EGCG or amifostine group were similar to that observed in the normal control 
group. Group I, the normal control; group II, RI exposed group; group III, administration of EGCG before RI exposure; group IV, administration 
of amifostine before RI exposure. EGCG, epigallocatechin-3-gallate; RI, radioiodine (Asterisks denote significant points).
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and human salivary gland cell. Saito et al. [26] also demonstrat-
ed that EGCG administration to this murine model protects sali-
vary glands from oxidative stress-induced tissue injury. That is, 
EGCG-mediated increased expression of antioxidants and re-
duced expression of autoantigens play an important role in the 
protection of salivary glands against oxidative stress-induced 
DNA damage and apoptosis in autoimmune sialadenitis of mice 
[26].
In the present study, significant intergroup differences in body 
weights were observed. In particular, animals in the EGCG or 
amifostine group weighed significantly more than animals in the 
RI group at 90 days post-RI. SG function importantly influences 
nutritional intake and general condition, and as a normal body 
weight usually reflects a healthy status, reductions of body 
weights in the EGCG or amifostine treated groups implies the 
radioprotective effect of EGCG or amifostine concerning SGs. 
Furthermore, lag times were lower and salivary flow rates were 
significantly higher in the EGCG or amifostine group than in 
the RI group, which suggests EGCG is as effective as amifostine 
in terms of protecting against RI-induced SG damage.
RI-exposed SGs showed cellular injury, acinar loss and disor-
ganization, glandular duct enlargement, and marked lipomatosis 
[4,27]. In a previous study, SGs in RI-exposed mice displayed 
pale cytoplasm, atypical ductal configuration, septal widening, 
lymphocyte infiltration, cytoplasmic vacuolization with pleo-
morphism, and elevated levels of tissue fibrosis [28]. In the pres-
ent study, mice pretreated with EGCG or amifostine showed 
significant changes in SG architectures at 90 days post-RI. In 
particular, the EGCG or amifostine group contained higher 
numbers of mucin containing acini than the RI group. Because 
mucin has low solubility, high viscosity, elasticity, and lubricity, 
and adheres well to surfaces, it is an important component of 
mastication, speech, swallowing, and the removal of bacteria 
from oral mucosa [29]. The EGCG or amifostine group also ex-
hibited less periductal and perivascular fibrosis than the RI 
group, and periductal fibrosis causes ductal stiffness and secre-
tion disorders [29]. Accordingly, we believe our observations of 
increased mucin quantities and reduced ductal fibrosis in EGCG 
or amifostine group indicate less gland dysfunction. Further-
more, our examination of filiform papillae showed that oral hy-
giene was better maintained in the EGCG or amifostine group.
 Apoptosis is a possible mechanism of RI-induced SG damage. 
Kutta et al. [27] found higher levels of apoptosis in the SGs of 
rabbits exposed to RI and observed the radioprotective effect of 
amifostine. In another study, TUNEL assays revealed more 
apoptotic cells in both acini and ducts in RI-exposed mice [28]. 
In the present study, the number of TUNEL-positive cells was 
significantly higher in the RI-exposed group than in controls, but 
EGCG or amifostine both reduced this increase. Thus, it appears 
EGCG or amifostine both blocks the apoptotic cascade.
Joseph et al. [4] also showed that antioxidant (Ocimum sanc-
tum) or amifostine pretreated SGs in rats exhibited greater 99mTc 
pertechnetate excretion than an RI alone. In the present study, 
we investigated spatial distributions of 99mTc pertechnetate up-
take and its excretion from SGs. Levels of 99mTc pertechnetate 
excretion were found to be markedly lower in RI-exposed group 
than in the control group, but excretion levels in the EGCG or 
amifostine treated groups were similar to in normal controls at 
90 days post-RI. These results support the view that EGCG or 
amifostine relieves ductal distress induced by RI.
Regarding topic worthy of future study, it is evident EGCG 
could sustain gland function by preventing apoptosis, but the 
mechanisms responsible for the protection it affords are poorly 
understood, and thus, further investigations are required to un-
veil the molecular mode of action of this unique phytochemical. 
Moreover, although it has been established EGCG induces dif-
ferential oxidative environments that favor tumor cell destruc-
tion and normal cell survival [30], further studies are needed to 
determine whether EGCG protects thyroid tumor cells.
In the present study, EGCG was found to protect SGs effec-
tively from RI-induced damage, and EGCG was observed to 
have a beneficial effect on gland histology and functional study 
and on extents of salivary excretion by SPECT in mice exposed 
to RI. The protective property of EGCG is believed to involve 
the reduction of ROS, which is induced by ionizing radiation in 
SG cells, especially in salivary ductal cells. In the case of differ-
entiated thyroid carcinoma, the use of amifostine as a radiopro-
tectant has not been unequivocally accepted. Controversial re-
ports regarding its efficacy underline the need to identify a bet-
ter radioprotectant for SGs exposed to high-dose RI therapy. The 
present study demonstrates the radioprotective effect of EGCG 
on mouse SGs exposed to RI. We recommend the use of EGCG 
be explored in detail to determine its effects on SG functions 
and its potential as a safe radioprotectant for use in patients 
with differentiated thyroid carcinoma scheduled to undergo RI 
therapy.
In conclusion, our findings suggest EGCG supplementation 
before RI therapy could have protective effects similar to ami-
fostine in terms of protecting SGs from RI-induced damage and 
possibly restoring RI-damaged SG functions.
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